HC Wainwright Downgrades Humanigen On Disappointing COVID-19 Study – What’s Next
HC Wainwright downgraded Humanigen Inc (NASDAQ:HGEN) to Neutral from Buy and removed the price target based on the removal of COVID-19…
What 10 Analyst Ratings Have To Say About Carrier Global
Over the past 3 months, 10 analysts have published their opinion on Carrier Global (NYSE:CARR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Analyst Ratings for Eastman Chemical
Over the past 3 months, 8 analysts have published their opinion on Eastman Chemical (NYSE:EMN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Where Boeing Stands With Analysts
Boeing (NYSE:BA) has observed the following analyst ratings within the last quarter:
Analyst Ratings for Five9
Over the past 3 months, 4 analysts have published their opinion on Five9 (NASDAQ:FIVN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
What 7 Analyst Ratings Have To Say About Ingersoll Rand
Within the last quarter, Ingersoll Rand (NYSE:IR) has observed the following analyst ratings:
Analyst Ratings for Equifax
Analysts have provided the following ratings for Equifax (NYSE:EFX) within the last quarter:
Telsey Advisory Cuts Price Target On Peloton Interactive By 26%
Telsey Advisory Group analyst Dana Telsey reiterated a Market Perform rating for Peloton Interactive Inc (NASDAQ: PTON), citing the lack of visibility into demand levels, profitability, and cash flow.
Amgen Touts Early Lumakras Combo Data In KRAS Cancer Settings
BMO Capital Markets says that while Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) + PD1i data was delayed to the August 7 presentation, it did get data on the Lumakras + SHP2 inhibitor combination.
Mizuho On Atara Biotherapeutics – Distinguish Between Small Numbers And Science Failure
Atara Biotherapeutics Inc (NASDAQ:ATRA) issued its anticipated interim analysis communication for its ATA188 Phase 2 progressive multiple sclerosis trial. Shares slumped…